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Inherited variation in the function of the drug metabolizing enzyme CYP2C19 was first
observed 40 years ago. The SNP variants which underpin loss of CYP2C19 function
have been elucidated and extensively studied in healthy populations. However, there
has been relatively meagre translation of this information into the clinic. The presence
of genotype-phenotype discordance in certain patients suggests that changes in the
regulation of this gene, as well as loss of function SNPs, could play a role in
deficient activity of this enzyme. Knowledge of the molecular mechanisms which control
transcription of this gene, reviewed in this article, may aid the challenge of delivering
CYP2C19 pharmacogenetics into clinical use.
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INTRODUCTION
CYP2C19 is important in the metabolism of many clinically
relevant drugs (Desta et al., 2002), particularly for several pro-
drugs that require hepatic activation including clopidogrel (Bauer
et al., 2011; Begg et al., 2012). The first reports of an autoso-
mal recessive inherited trait that resulted in poor metabolism
of the prototypical CYP2C19 substrate, mephenytoin, appeared
many years ago (Kupfer et al., 1979). The correlation between
the poor metabolizer phenotype and loss of function genotype
has been comprehensively studied in healthy populations (Desta
et al., 2002). Screening for these genetic variants is one approach
to individualize therapy for drugs which are substrates for this
enzyme. However to be useful genotype must be predictive of
phenotype, not only in healthy populations but also in the clinical
context (Helsby, 2008). The presence of genotype-phenotype dis-
cordance in certain morbidities (Williams et al., 2000; Frye et al.,
2002; Helsby et al., 2008), suggests that an acquired deficiency
in the activity of this enzyme also occurs. Factors which regu-
late CYP2C19 transcription could play an additional role in the
pharmacogenomic variation of this enzyme. The current knowl-
edge of the molecular mechanisms which control expression of
the CYP2C19 gene, such as the coding and regulatory region cis-
variants as well as trans-acting epigenomic factors, are reviewed
in this article.
CYP2C19 GENE VARIANTS
The role of cis-acting variants of CYP2C19 have been extensively
characterized and the polymorphic expression of these genetic
variants results in inter-individual variation in CYP2C19 activ-
ity. More than 28 variant alleles in CYP2C19 have been identified
(http://www.cypalleles.ki.se/, access date August 19, 2012) and
are summarized in Table 1. Many of these variants have relatively
low frequency however, the SNPs which lead to the CYP2C19 ∗2
and CYP2C19 ∗3 alleles are common and have been the most
extensively studied. These SNPs, c.681G>A, and c.636G>A,
cause aberrant splicing and a premature stop codon respectively
and result in null function. Individuals who are homozygous vari-
ant for either of these alleles are poor metabolizers of certain
drugs. The allele frequency of these null function variants varies
with ethnicity (Xie et al., 2001; Sistonen et al., 2009). A particu-
larly high prevalence of both ∗2 and ∗3 is observed in Vanuatu
and Papua New Guinea, accounting for up to 70.8% (∗2) and
13.3% (∗3) of these alleles in the Vanuatu population, and up to
42.3% and 31.5%, respectively, in the Papua New Guinea popu-
lation (Kaneko et al., 1997; Hsu et al., 2008). This exceptionally
high expression in Melanesia may reflect an unidentified evolu-
tionary pressure. For further information on these null function
alleles and the drug substrates of CYP2C19 readers are directed
to review articles that have focused on CYP2C19 pharmacogenet-
ics such as Desta et al. (2002). In addition to genetic variation
in the coding region of the gene, promoter region variation may
also influence transcriptional expression and ultimately activity.
The CYP2C19 ∗17 allele (g.–3402C>T and g.–806C>T) has been
the focus of studies to identify increased function variants of
this gene. Ethnic variation in the prevalence of this allele is also
observed with a relatively low allele frequency (<5%) in Japanese
and Chinese populations, compared with a higher incidence in
European and African populations (∼15–30%) (Li-Wan-Po et al.,
2010).
REGULATORY POLYMORPHISMS
CYP2C19∗17
CYP2C19 ∗17 was first identified in 2006 (Sim et al., 2006).
Electrophoretic mobility shift assays (EMSA) detected binding
of human hepatic nuclear proteins at −806T but not −806C.
A potential GATA binding site at this position was identified
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Table 1 | CYP2C19 gene variants.
Allele Characteristic SNPa Functional change References
cDNA Gene Effect
CYP2C19 ∗1 None1 None None Normal Romkes et al., 1991
CYP2C19 ∗2 681G>A2 19154G>A Splicing defect Non-functional De Morais et al., 1994b; Ibeanu et al.,
1998b; Fukushima-Uesaka et al., 2005;
Lee et al., 2009; Satyanarayana et al.,
2009a
CYP2C19 ∗3 636G>A3 17948G>A Premature stop codon
(W212X)
Non-functional De Morais et al., 1994a;
Fukushima-Uesaka et al., 2005
CYP2C19 ∗4 1A>G4 1A>G GTG initiation codon Non-functional Ferguson et al., 1998; Scott et al., 2011
CYP2C19 ∗5 1297C>T5 90033C>T R433W Non-functional Xiao et al., 1997; Ibeanu et al., 1998a
CYP2C19 ∗6 395G>A 12748G>A R132Q Non-functional Ibeanu et al., 1998b
CYP2C19 ∗7 19294T>A Splicing defect Non-functional Ibeanu et al., 1999
CYP2C19 ∗8 358T>C 12711T>C W120R Decreased in vitro Ibeanu et al., 1999
CYP2C19 ∗9 431G>A 12784G>A R144H Decreased in vitro Blaisdell et al., 2002
CYP2C19 ∗10 680C>T 19153C>T P227L Decreased in vitro Blaisdell et al., 2002
CYP2C19 ∗11 449G>A 12802G>A R150H Similar to wild type in vitro Blaisdell et al., 2002
CYP2C19 ∗12 1473A>C 90209A>C X491C; 26 extra amino
acids
Unstable in vitro Blaisdell et al., 2002
CYP2C19 ∗13 1228C>T 87290C>T R410C Similar to wild type in vitro Blaisdell et al., 2002
CYP2C19 ∗14 50T>C 50T>C L17P Not determined Blaisdell et al., 2002
CYP2C19 ∗15 55A>C 55A>C I19L Not determined Blaisdell et al., 2002
CYP2C19 ∗16 1324C>T6 90060C>T R442C Not determined Morita et al., 2004
CYP2C19 ∗17 3402C>T;
−806C>T
Increased transcription
in vitro; Should not be termed
Ultrarapid (UM)
Sim et al., 2006
CYP2C19 ∗18 986G>A 80156G>A;
87106T>C
R329H Not determined Fukushima-Uesaka et al., 2005
CYP2C19 ∗19 151A>G 151A>G;
87106T>C
S51G Not determined Fukushima-Uesaka et al., 2005
CYP2C19 ∗207 636G>A 17948G>A Premature stop codon
(W212X) and D360N
Non-functional Fukushima-Uesaka et al., 2005
CYP2C19 ∗218 681G>A 19154G>A;
–98T>C
splicing defect and
A161P
Non-functional Fukushima-Uesaka et al., 2005;
Satyanarayana et al., 2009a
CYP2C19 ∗22 557G>C 17869G>C R186P Not determined Matimba et al., 2009
CYP2C19 ∗23 271G>C 12455G>C G91R Not determined Zhou et al., 2009
CYP2C19 ∗24 1004G>A;
1197A>G
80174G>A;
87259A>G
R335Q Not determined Zhou et al., 2009
CYP2C19 ∗25 1344C>G 90080C>G F448L Not determined Zhou et al., 2009
CYP2C19 ∗26 766G>A 19239G>A D256N Decreased in vitro Lee et al., 2009
CYP2C19 ∗27 –1041G>A Decreased in vitro Drögemöller et al., 2010
CYP2C19 ∗28 1120G>A −2020C>A;
−1439T>C;
80290G>A
V374I No significant decrease
in vitro
Drögemöller et al., 2010
aOnly major SNP or alteration(s) responsible for the phenotype of the corresponding allele are shown. Adapted from http://www.cypalleles.ki.se/
1The presence of additional SNP can further sub-classify individuals as ∗1B (99C>T; 991A>G) or ∗1C (991A>G). This results in an I331V change but does not alter
activity.
2The presence of additional SNP can further sub-classify individuals as ∗2A, ∗2B, ∗2C, and ∗2D. Of these variants ∗2C and ∗2D harbor a SNP in the 5 ′ promoter
region (−98T>C) that may have a functional effect.
3The presence of additional SNP can further sub-classify individuals as ∗3A (1251A>C) and ∗3B (1078G>A; 1251A>C).
4The presence of −3402C>T; −806C>T SNP in the promoter can further sub-classify individuals as ∗4B.
5The presence of 99C>T; 991A>G, can further sub-classify individuals as ∗5B.
6Existence of the CYP2C19 ∗2 polymorphism 681G>A on the same allele cannot be excluded.
7Also known as CYP2C19 ∗3B.
8Also known as CYP2C19 ∗2C.
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in silico and it was hypothesized that the −806C>T variant could
result in increased transcription of CYP2C19. However, to date
GATA-dependent transactivation at the −806C>T site has not
been directly demonstrated. Indeed it is of note that follow-
ing co-transfection with GATA-4 or GATA-6, −806T>C variant
reporter constructs did not have increased luciferase activity com-
pared with wildtype constructs (Mwinyi et al., 2010b). Although
GATA may not be involved, transfection of reporter constructs of
the −0.9 Kb of the 5′ flanking region into mice lead to an increase
in transcription in the −806T mutant compared with wildtype
construct. However a range of overlapping individual luciferase
activities were observed in wildtype and mutant constructs. To
date no direct evidence of correlations between CYP2C19 ∗17
genotype status and increased transcription or protein expres-
sion in human liver biobanks has been reported. Despite the lack
of direct evidence this genotype is often described as increasing
the expression of the enzyme (protein) and many investigators
have categorized individuals who carry this variant allele as ultra-
rapid metabolizers (UM). When CYP2C19 activity is measured
in vivo using drug to metabolite ratios of probe substrates such
as omeprazole it is clear that the mean activity of CYP2C19 is
higher in homozygous ∗17/∗17 subjects than in individuals with
the ∗1/∗1 genotype (Baldwin et al., 2008). However, the activity
in ∗17/∗17 subjects overlaps the heterogenous activity observed
in ∗1/∗1 subjects (Baldwin et al., 2008). Similar effects have
been observed with other drugs such as escitalopram, clopido-
grel and voriconazole (Li-Wan-Po et al., 2010). The high activity
in some ∗1/∗1 subjects may be due to other currently unidentified
increased activity variants. However currently ∗17/∗17 subjects do
not appear to be a separate population and fall within the nor-
mal distribution of wildtype CYP2C19 activity, therefore should
not be classified as an ultra-rapid phenotype. Moreover, the ultra-
rapid metabolizer phenotype observed with CYP2D6 substrates
is typically due to gene duplication and associated copy number
variation, and it is important to note that copy number vari-
ation for CYP2C19, appears to be absent (Drögemöller et al.,
2010; Devendran et al., 2012). Further identification of additional
SNP in the 5′-up-stream region of CYP2C19 may clarify the wide
heterogeneity of activity in ∗1/∗1 individuals.
OTHER PROMOTER REGION VARIANTS
Publication of the promoter sequence of CYP2C19 gene
(Genbank accession #AF354181) led to the identification of eight
SNP in the −1.833 Kb promoter region (Arefayene et al., 2003).
Resequencing of genomic DNA from 92 individuals of varied
ethnicity identified 13 SNP in the −1.46 Kb up-stream region
of the gene (Blaisdell et al., 2002). Extensive characterization of
the 5′-regulatory region of CYP2C19 also identified a further
seven SNP novel variants in the enhancer region and five SNP
in the promoter region in Japanese subjects (Fukushima-Uesaka
et al., 2005). Eight novel SNP were also detected in the −1.7 Kb
promoter region in a South Indian population (Satyanarayana
et al., 2009b). More recently resequencing of −2.095Kb of the
5′-up-stream region of CYP2C19 identified two additional novel
SNP (g.−2030C>T and g.−2020C>A). These SNPs, in com-
bination with a previously identified SNP in the 5′promoter
(g.−1439T>C) and the g.80290 G>A SNP in exon 7, result
in the CYP2C19 ∗28 genotype (Table 1) (Drögemöller et al.,
2010). Extensive ethnic variation in the frequency of pro-
moter/enhancer region SNP is evident from the above studies.
Identification of the functional effects of these 35 novel SNP iden-
tified up-stream of the translational start site is important for
our understanding of the variable expression and activity of this
enzyme.
Regions of negative and positive regulatory control of
CYP2C19 were observed following transient expression of
luciferase reporter deletion constructs in HepG2 cells (Arefayene
et al., 2003). Transient expression into HepG2 cells of
luciferase reporter deletion constructs between positions−153 bp
and −17 bp significantly decreased luciferase activity, suggest-
ing effects on transcription factor binding. In contrast deletion
from −650 bp to −363 bp increased luciferase activity, indicat-
ing the presence of repressor regulation in this region. Using
nine different constructs of the CYP2C19 5′ promoter region
(−1.6 Kb) transfected into HepG2 cells, Satyanarayana et al.
(2011) showed that the presence of either the −98T>C SNP in
combination with −1498T>G or the combination of −98T>C,
−779A>C, −1051T>C, and −1418C>T, significantly increased
luciferase activity. The SNP −98T>C is within both a potential
CCAAT displacement protein (CDP) binding site and a poten-
tial GATA-1 site (Satyanarayana et al., 2009b). In silico analysis
indicated that interaction of the CDP repressor with its puta-
tive binding site was weaker in the presence of the −98C variant
whereas GATA-1 had a high predicted binding activity in the
presence of the normal −98T. Hence the functional consequence
may be that in wildtype subjects (−98TT or CT) repression of
GATA-1 binding will be greater than in homozygous −98CC
subjects. Indeed, the presence of −98TT genotype appears to
decrease the activity of the enzyme compared with the −98CT
or −98CC genotype in subjects probed in vivo with proguanil
(Satyanarayana et al., 2009a). This is suggestive of a functional
effect of a transcriptional repressor at this region of the pro-
moter, in agreement with the early data from Arefayene et al.
(2003). It is of interest to note that −98 C>T displays linkage
with the c.681G>A (∗2) SNP (Fukushima-Uesaka et al., 2005;
Satyanarayana et al., 2009b) as CYP2C19 ∗21, also known as
CYP2C19 ∗2C (Table 1).
Most recently the g.−1041G>A SNP in theCYP2C19 ∗27 allele
(Table 1) has also been demonstrated to have functional conse-
quences. Significantly decreased luciferase activity was observed
in a construct transfected into HepG2 cells, whereas the promoter
region SNP (−2030C>T;−1439T>C) in the CYP2C19 ∗28 allele
did not significantly decrease activity (Drögemöller et al., 2010).
Thus, to date only three of the 35 SNP identified in the proxi-
mal five region of CYP2C19 appear to be associated with changes
in gene transcription: −806C>T (∗17), −1041G>A (∗27)
and −98 C>T (∗21).
TRANSCRIPTION FACTOR BINDING SITES IN CYP2C19
Many predicted or putative sites for transcription factor binding
have been reported for CYP2C19. However, functional transcrip-
tion factor binding sites have only been demonstrated for the
ligand activated nuclear receptors ERα (NR3A1) (Mwinyi et al.,
2010a), CAR (NR1I3), and GR (NR3C1) (Chen et al., 2003), and
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the transcription factors HNF3γ (FOXA3) (Bort et al., 2004) and
GATA-4 (Mwinyi et al., 2010b), (Figure 1).
The constitutive androstane receptor response element
(CAR-RE) at −1891/−1876 in the promoter region of CYP2C19
has been shown to functionally active. Binding of CAR pro-
tein occurs as a monomer or heterodimer with the retinoid X
receptor (RXR) and pregnane X receptor (PXR). Deletion of this
site completely abolishes binding (Chen et al., 2003). Expression
of CYP2C19 appears to be more sensitive to the effects of co-
transfection with CAR than with PXR, nevertheless luciferase
activity can be induced by the PXR activator rifampicin (Chen
et al., 2003), a known inducer of CYP2C19 activity in patients
(Feng et al., 1998). There is a significant correlation between CAR
mRNA and CYP2C19 transcription in human liver (Wortham
et al., 2007). Deletion constructs have demonstrated the func-
tional activity of a glucocorticoid responsive element (GRE) at
−1750/−1736b, and dexamethasone can also induce the expres-
sion of a CYP2C19 construct containing this GRE in transfected
HepG2 and Caco2 cells (Chen et al., 2003).
A functional estrogen response element (ERE) half site has
been identified in CYP2C19 at position −151/−147 (Mwinyi
et al., 2010a). This GGTCA motif binds ERα but not ERβ. Both
17-β estradiol and 17-α ethinylestradiol down-regulate reporter
luciferase activity in Huh-7 transfected cells co-transfected with
ERα. However, the partial agonists 4-hydroxytamoxifen and
raloxifene had no effect onCYP2C19 transcription (Mwinyi et al.,
2010a). Interestingly mutation of this ERE half site decreases but
does not abolish luciferase activity. Chromatin immunoprecipita-
tion of Huh-7 cells combined with q-PCR demonstrated that ERα
was associated with this ERE half site in the CYP2C19 promoter.
17-α ethinylestradiol stimulated this interaction of ERα with the
promoter whereas 4-hydroxytamoxifen abolished the interaction.
Preliminary data suggested that treatment of primary hepatocytes
with 17-β estradiol or 17-α ethnylestradiol decreased CYP2C19
mRNA expression (Mwinyi et al., 2010a). This is in contrast
to recent data which found that estradiol did not influence the
expression of CYP2C19 (Choi et al., 2012). The biotransforma-
tion of estrogens by CYP enzymes results in a half-life of estradiol
in human hepatocytes of <34min. Thus concentration depen-
dent ligand bindingmay influence transactivation of CYP2C19 by
ERα in hepatocytes.
In addition to the three ligand-activated transcription fac-
tors described above, two additional transcription factor pro-
teins have also been demonstrated to be important in CYP2C19
transcription:- FOXA3 and GATA-4. Three hepatocyte nuclear
factor 3 gamma (HNF3γ) sites, (−313/−298, −560/−545,
−623/−608), have been identified in the CYP2C19 promoter
(Bort et al., 2004). Cotransfection with HNF3γ in luciferase
reporter assays as well as overexpression of HNF3γ in HeLa and
hepatoma cells significantly increased expression of CYP2C19
(Bort et al., 2004). HNF3γ is member of the forkhead box/winged
helix family of transcription factors and is also known as FOXA3.
This transcription factor is important in the expression of liver-
specific genes and the development of hepatic lineage. In con-
trast, co-transfection with HNF4α, did not increase luciferase
expression despite the presence of HNF4α sites at −186/−174,
−152/−140 (Kawashima et al., 2006). These sites do not appear
to be functional as deletion constructs, indicating that HNF4α
cannot increase transcription of CYP2C19 (Bort et al., 2004) and
also indicate thatHNF4α protein does not bind toCYP2C19 (Bort
et al., 2004; Rana et al., 2010).
GATA-4 is a member of the zinc-finger transcription fac-
tor family. Two adjacent GATA binding motifs (TATC) have
been detected in the CYP2C19 promoter at −165/−162
and −159/−156 (Mwinyi et al., 2010b). Wildtype and dele-
tion constructs containing destructive mutations in each of
the GATA sites were transfected into HepG2 or Huh-7 cells.
Significant up-regulation of luciferase activity of these constructs
FIGURE 1 | Functional transcription factor binding sites in the 2.0 kb
5′-promoter region of CYP2C19. The binding factor CAR (constitutive
androstane receptor; NR113) acts at the CAR response element
(−1891/−1876bp). NR113 can also hetero-dimerise with retinoid X receptor
(RXR) and pregnane X receptor (PXR) to transactivate CYP2C19 (Chen et al.,
2003). The glucocorticoid receptor (GR; NR3C1) acts at the glucocorticoid
response element (GRE) at position −1750/−1736bp (Chen et al., 2003).
Hepatocyte nuclear factor 3 gamma (HNF3γ) is member of the forkhead
box/winged helix family of transcription factors and is also known as FOXA3.
Three functional FOXA3 sites, (−313/−298, −560/−545, −623/−608bp) exist
in the CYP2C19 promoter (Bort et al., 2004). GATA-4 is a member of the
zinc-finger transcription factor family. Two adjacent GATA binding motifs
(TATC) are found between −165/−156bp, and GATA-4 predominantly binds to
site I (−165/−162bp). The repressor protein, Friend of GATA (FOG-2),
attenuates the effect of GATA-4 binding (Mwinyi et al., 2010b). Estrogen
receptor-α (ERα) binds to the estrogen receptor element (ERE) half site
at −151/−147bp. Mutation of this site decreases but does not abolish
transcription (Mwinyi et al., 2010a).
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was observed when co-transfected with either GATA-4 or GATA-
2. Deletion of this double GATA binding site completely abolished
transcription. However, EMSA analysis demonstrated nuclear
extracts predominantly bind to site I (−165/−162) and chro-
matin immunoprecipitation confirmed that GATA-4 was associ-
ated with the CYP2C19 promoter. The GATA repressor protein
friend of GATA 2 (FOG-2), also known as zinc finger protein
multitype-2, attenuates the effect of GATA-4 and may also have
a role to play in the regulation of CYP2C19 transcription. GATA-
4 is an important liver associated transcription factor (Molkentin,
2000).
More recently, it has been proposed that the following tran-
scription factors and binding sites may also be important
in the transcription of CYP2C19:- ATF-2 (−806 to −786),
CEBP-β (−1505/−1491 and −1443/−1429), CDP repressor pro-
tein (−105/−87), GATA-1 (−103/−91) and an additional GRE
(−828/−810), however further functional analysis is required to
establish the relevance, if any, of these factors (Satyanarayana
et al., 2011). The weak correlations between PXR, ARNT, and
HNF1α genes with CYP2C19 mRNA expression in human liver
suggests that these transcriptional regulators do not extensively
contribute to CYP2C19 expression (Wang et al., 2011).
Trans ACTING FACTORS
In contrast to cis regulation due to genetic variants, the trans-
acting factors which control CYP2C19 expression have been
largely ignored. Knowledge of epigenomic control of CYP2C19,
via factors such as altered expression of transcription factor genes
or the effects of noncoding RNA, is limited. A number of studies
have identified that environmental (rather than inherited genetic)
effects such as pregnancy, old age, cancer, and congestive heart
failure (Williams et al., 2000; Frye et al., 2002; McGready et al.,
2003; Ishizawa et al., 2005) can all lead to an acquired alteration
in CYP2C19 activity. The observed change in activity can lead to
genotype-phenotype discordance, such that a poor metabolizer
status can be observed in individuals who are not homozygous
variant for null function alleles. Thismay be due toCYP2C19 gene
down-regulation as has been observed following incubation of the
inflammatory cytokines, IL-6 and TGF-β, with primary human
hepatocytes (Aitken andMorgan, 2007). The mechanisms for this
down-regulation of CYP2C19 have not been elucidated to date
but could include direct effects on gene transcription (e.g., CpG
methylation), up-stream effects on the expression or activity of
transcription factors or post-translational regulation ofCYP2C19.
EPIGENETICS
Tissue specific regulation of genes can be the result of epigenetic
regulation and it is notable that the expression of CYP2C19 is
restricted to the liver and intestine (Läpple et al., 2003; Hayashi
et al., 2011; Bourgine et al., 2012). Quantification of gene tran-
scripts (cDNA copy number) indicates the same range and
median expression of CYP2C19 mRNA in the intestine as in the
liver. However, the authors could not detect an intra-individual
correlation between CYP2C19 expression in samples of liver and
intestine from each patient expression. Hence there may be inde-
pendent regulation of transcription of CYP2C19 in these tissues
(Läpple et al., 2003). One possible mechanism of tissue specific
expression is epigenetic control via methylation of CpG islands in
the gene or by histone modifications such as acetylation.
Remarkably little is known about epigenetic regulation of
CYP2C19 (Ingelman-Sundberg et al., 2007). However a small
number of CpG islands can be detected in the gene (Figure 2).
Methylation of CpG sites in the promoter region of a target gene
can affect the physical binding of transcription factors to regulate
gene expression. In the case ofCYP2C19 these CpG islands are not
associated with the promoter region. However, DNAmethylation
can also act via an indirect mechanism on chromatin configura-
tion. There is currently no data regarding the methylation status
of the CYP2C19 CpG islands.
DNA methylation can lead to a phenomenon known as allelic
expression imbalance. The difference in expression levels between
two alleles of CYP2C19 typically occurs due to genetic polymor-
phisms (e.g., a heterozygous carrier of ∗3). However epigenetic
silencing of an allele (e.g., methylation) can also result in the pref-
erential expression of one of the two alleles. Allelic expression
imbalance is assessed directly by the relative quantitation of an
intragenic marker allele in cells or tissues. In the absence of any
cis-acting control on transcription the allelic ratio should be 1
FIGURE 2 | CpG islands identified in CYP2C19. The complete CYP2C19
sequence (Ensembl Gene ID ENSG00000165841; National Centre for
Biotechnology Information (NCBI); Entrez core nucleotide sequence NM
000769) was analyzed using CpG Island finder, http://cpgislands.usc.edu/.
Potential CpG island regions were determined using the following
parameters %GC = 50–55%, ObsCpG/ExpCpG = 0.6, length = 100–500bp,
gap between adjacent islands = 100bp. Up to five CpG islands were
identified in CYP2C19. Notably most of these CpG islands are down-stream
of the ATG initiation codon (i.e., within the coding region of the gene) and are
not associated with the 5′proximal promoter. The CpG islands are shown as
red bars at 485, 85179, 87789, 130071, and 142631bp. The 5′ upstream
region is shown in grey and the coding region of the gene in blue.
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(i.e., equal amounts from each allele). In liver samples from het-
erozygous individuals, the cis-acting variant of CYP2C19 (∗2;
rs4244285) accounts for the majority of the allelic expression
imbalance observed. However, there was only a weak correla-
tion (p = 0.047) between CYP2C19 mRNA expression and this
SNP in these 96 human livers. This suggests that variability in
CYP2C19 expression is not fully accounted for by known cod-
ing region polymorphisms. Interestingly, the non-coding marker
SNP in intron 3, (rs 4388808), was associated with up to 47%
of allelic expression imbalance for CYP2C19 (Wang et al., 2011).
This confirms that in addition to cis-acting polymorphic vari-
ants, there are factors which influence the regulatory control of
CYP2C19 RNA transcription or stability. Hence epigenetic factors
may also affect the hepatic expression level of CYP2C19.
POST-TRANSLATIONAL REGULATION OF CYP2C19
In addition to transcriptional regulation, post-transcriptional
regulation may influence the expression of CYP2C19. Noncoding
RNA, such as microRNA (miR), can bind to recognition sites
(MRE) in the 3′-untranslated region (3′UTR) or in the cod-
ing region of target genes and thereby repress gene translation.
The role of miR regulation of CYP2C19 was until recently not
known, as in silico prediction of miR regulation of CYP2C19
was not available due to the lack of information about the 3′-
UTR of the gene (Ramamoorthy and Skaar, 2011). However,
it has recently been reported that the 3′UTR of CYP2C19 con-
tains two putative MRE for miR-103/107 at 222–242 bp and
138–152 bp down-stream of the stop codon. These MRE contain
one nucleotide mismatch, however, ectopic addition of precur-
sors of miR-103/107 to human hepatocytes significantly down-
regulated CYP2C19 immunoreactive protein (Zhang et al., 2012).
This preliminary data suggests that post-transcriptional regu-
lation of the constitutive expression of CYP2C19 may be an
additional contributing factor to inter-individual variation in the
expression of this enzyme in subjects who do not express SNP
variants.
CONTROL OF TRANSCRIPTION FACTOR ACTIVITY
Another mechanism which could account for variation in the
regulation of CYP2C19 expression is the effect of both genomic
and environmental factors which influence transcription factor-
binding to the promoter region. SNP variants present in the
promoter region have been discussed above, however up-stream
effects on the expression or activity of transcription factors may
also play a role in CYP2C19 transcription. It is important to
appreciate that as well as altered expression of transcription fac-
tor genes the function of ligand-activated factors (ERα, CAR, GR)
can be influenced by variation in the levels of endogenous ligands,
such as estrogens and glucocorticoids. Hence environmental fac-
tors may influence the activity of transcription factors important
forCYP2C19 transcription. The ability of ERα, CAR, GR, FOXA3,
and GATA-4 to interact with other transcription factors may add
further complexity to the regulation of CYP2C19. For example,
estrogen-dependent activation of ERα results in binding to the
ERE. This appears to result in a down-regulation of CYP2C19
transcription (Mwinyi et al., 2010a). Changes in CYP2C19 activ-
ity have been reported in women during pregnancy and whilst
using oral contraceptives (McGready et al., 2003), suggesting
a regulatory role for estrogens on CYP2C19 activity. However,
ligand-independent activation of ERα also occurs. ERα can act
via a non-classical pathway to alter the activities of other tran-
scription factors (e.g., Sp1, AP-1, or NF-kappaB) at their cognate
sites on DNA. The role of interactions of ER-α with other tran-
scription factors that regulate CYP2C19 cannot be discounted.
This may account for why mutation constructs of the ERE site
decrease but do not abolish CYP2C19 transcription in the pres-
ence of ligand activated ER-α (Mwinyi et al., 2010a). In addition,
GATA-4 co-operates with FOXA3 to stimulate albumin gene tran-
scription in liver cells (Cirillo et al., 2002). Moreover, FOXA3
and GATA-4 can act as pioneer factors. Once bound these pio-
neer factors relax the adjacent chromatin to allow other factors
to bind. Interestingly GATA-4 appears to be able to direct the
association of ERα in certain contexts (Miranda-Carboni et al.,
2011).
Understanding the genomic control of CYP2C19 expression
is important in order to increase our understanding of the
observed phenotype-genotype discordance in morbidity. This
acquired deficiency may influence the sensitivity and specificity
of CYP2C19 pharmacogenetic tests in clinical contexts. A corre-
lation between CYP2C19 mRNA and the expression of CYP2C9
and CYP3A4 has been observed (Wang et al., 2011) and Bayesian
network analysis suggests that CYP2C19 is the master regulator
of CYP2C9, CYP3A7, CYP3A4, and CYP3A43 (Yang et al., 2010).
Hence further study of the mechanisms which regulate CYP2C19
may also increase our understanding of the regulation of other
important drug metabolizing enzymes.
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